In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Calliditas Therapeutics AB

https://www.calliditas.se/en/

Latest From Calliditas Therapeutics AB

Novartis Challenger To Alexion Advances In Rare Kidney Disease

First-in-class iptacopan could help Novartis expand into kidney disease, and take on Alexion’s blockbuster rare disease franchise.

Companies Commercial

EU Accelerated Assessment Tracker

Calliditas Therapeutics' lead product candidate Nefecon will be fast-tracked at the EMA once the marketing application is filed. Takeda and Bayer are hoping for the same success with maribavir and copanlisib respectively.

Europe Review Pathway

Takeda’s CMV Infection ‘Game-Changer’ Among EU Fast-Track Hopefuls

Takeda, Calliditas and Bayer are set to learn whether the European Medicines Agency will grant their respective products accelerated assessment status when they file for pan-EU marketing approval.

Europe Review Pathway

How Sweden's Calliditas Built Up Its US Presence And Development Portfolio

Interview: delivering on its US business strategy during the COVID-19 pandemic has required a focus on communication, according to Calliditas CEO Renee Aguiar-Lucander.

Renal Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Pharmalink AB
UsernamePublicRestriction

Register